Avidity biosciences honors rare disease day® and global efforts to support people and families impacted by rare neuromuscular diseases

San diego , feb. 28, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of rare disease day®. "rare disease day represents an important opportunity for all of us, including people living with rare diseases, their friends, family and caregivers, and advocacy organizations around the world, to spotlight the many challenges that rare diseases present in daily living," said sarah boyce, president and chief executive officer at avidity.
RNA Ratings Summary
RNA Quant Ranking